Gilead Hopes Selectivity Will Ease Safety Labeling For Filgotinib
On pace to file selective JAK1 inhibitor filgotinib for US approval in RA by year’s end, Gilead says the drug’s safety profile may allow for a labeling advantage compared with other drugs in the class.
